AbCellera Biologics Inc. Operating Income
AbCellera Biologics Inc. (ABCL) reported Operating Income of -$62.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- AbCellera Biologics Inc. operating income (loss) for the quarter ending 2026-06-30 was -$62.78M.
- AbCellera Biologics Inc. operating income (loss) for the quarter ending 2026-03-31 was -$57.52M.
- AbCellera Biologics Inc. operating income (loss) for the quarter ending 2025-12-31 was -$28.58M.
- AbCellera Biologics Inc. operating income (loss) for the quarter ending 2025-09-30 was -$76.28M.
- AbCellera Biologics Inc. operating income (loss) for fiscal 2025 was -$217.10M.
- AbCellera Biologics Inc. operating income (loss) for fiscal 2024 was -$314.77M.
- AbCellera Biologics Inc. operating income (loss) for fiscal 2023 was -$237.21M, a 209.56% decline from fiscal 2022.
- AbCellera Biologics Inc. operating income (loss) for fiscal 2022 was $216.51M, a 5.92% increase from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$62.78M 10-Q · filed 2026-08-05 | -$120.30M 10-Q · filed 2026-08-05 | -$148.88M derived: sum of 3 quarters · filed 2026-08-05 | -$225.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$57.52M 10-Q · filed 2026-05-11 | -$86.10M derived: sum of 2 quarters · filed 2026-05-11 | -$162.38M derived: sum of 3 quarters · filed 2026-05-11 | -$211.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$28.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$104.86M derived: sum of 2 quarters · filed 2026-02-24 | -$154.44M derived: sum of 3 quarters · filed 2026-08-05 | -$217.10M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$76.28M 10-Q · filed 2025-11-06 | -$125.86M derived: sum of 2 quarters · filed 2026-08-05 | -$188.52M 10-Q · filed 2025-11-06 | -$261.28M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$49.59M 10-Q · filed 2026-08-05 | -$112.25M 10-Q · filed 2026-08-05 | -$185.00M derived: sum of 3 quarters · filed 2026-08-05 | -$278.66M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$62.66M 10-Q · filed 2026-05-11 | -$135.41M derived: sum of 2 quarters · filed 2026-05-11 | -$229.08M derived: sum of 3 quarters · filed 2026-05-11 | -$322.53M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$72.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$166.42M derived: sum of 2 quarters · filed 2026-02-24 | -$259.87M derived: sum of 3 quarters · filed 2026-02-24 | -$314.77M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$93.66M 10-Q · filed 2025-11-06 | -$187.12M derived: sum of 2 quarters · filed 2025-11-06 | -$242.01M 10-Q · filed 2025-11-06 | -$308.06M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$93.45M 10-Q · filed 2025-08-07 | -$148.35M 10-Q · filed 2025-08-07 | -$214.40M derived: sum of 3 quarters · filed 2026-02-24 | -$269.29M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$54.89M 10-Q · filed 2025-05-08 | -$120.95M derived: sum of 2 quarters · filed 2026-02-24 | -$175.84M derived: sum of 3 quarters · filed 2026-02-24 | -$227.23M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$66.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$120.94M derived: sum of 2 quarters · filed 2026-02-24 | -$172.33M derived: sum of 3 quarters · filed 2026-02-24 | -$237.21M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$54.89M 10-Q · filed 2024-11-04 | -$106.28M derived: sum of 2 quarters · filed 2024-11-04 | -$171.15M 10-Q · filed 2024-11-04 | -$208.93M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$51.39M 10-Q · filed 2024-08-06 | -$116.26M 10-Q · filed 2024-08-06 | -$154.04M derived: sum of 3 quarters · filed 2025-02-27 | -$116.31M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$64.87M 10-Q · filed 2024-05-07 | -$102.65M derived: sum of 2 quarters · filed 2025-02-27 | -$64.92M derived: sum of 3 quarters · filed 2025-02-27 | -$73.31M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$37.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$43.00K derived: sum of 2 quarters · filed 2025-02-27 | -$8.44M derived: sum of 3 quarters · filed 2025-02-27 | $216.51M 10-K · filed 2025-02-27 |
| 2022-09-30 | $37.73M 10-Q · filed 2023-11-02 | $29.34M derived: sum of 2 quarters · filed 2023-11-02 | $254.29M 10-Q · filed 2023-11-02 | $335.84M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | -$8.40M 10-Q · filed 2023-08-03 | $216.55M 10-Q · filed 2023-08-03 | $298.11M derived: sum of 3 quarters · filed 2024-02-20 | $270.01M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $224.95M 10-Q · filed 2023-05-04 | $306.50M derived: sum of 2 quarters · filed 2024-02-20 | $278.41M derived: sum of 3 quarters · filed 2024-02-20 | $271.37M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $81.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $53.46M derived: sum of 2 quarters · filed 2024-02-20 | $46.42M derived: sum of 3 quarters · filed 2024-02-20 | $204.41M 10-K · filed 2024-02-20 |
| 2021-09-30 | -$28.10M 10-Q · filed 2022-11-08 | -$35.13M derived: sum of 2 quarters · filed 2022-11-08 | $122.86M 10-Q · filed 2022-11-08 | $283.72M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | -$7.03M 10-Q · filed 2022-08-09 | $150.97M 10-Q · filed 2022-08-09 | $311.82M derived: sum of 3 quarters · filed 2023-02-21 | $310.05M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $158.07M 10-Q · filed 2022-05-10 | $318.85M derived: sum of 2 quarters · filed 2023-02-21 | $317.08M derived: sum of 3 quarters · filed 2023-02-21 | $316.23M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $160.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $159.01M derived: sum of 2 quarters · filed 2023-02-21 | $158.15M derived: sum of 3 quarters · filed 2023-02-21 | $156.03M 10-K · filed 2023-02-21 |
| 2020-09-30 | -$1.77M 10-Q · filed 2021-11-10 | -$2.62M derived: sum of 2 quarters · filed 2021-11-10 | -$4.74M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$854.00K 10-Q · filed 2021-08-13 | -$2.98M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$2.12M 10-Q · filed 2021-05-14 | |||
| 2019-12-31 | -$4.12M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |